BenevolentAI announces 3-year collaboration expansion with AstraZeneca focused on systemic lupus erythematosus and heart failure

The expansion builds on the collaboration initiated in 2019 and adds systemic lupus erythematosus (SLE) and heart failure (HF) to ongoing work to identify multiple novel targets in chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF).